Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese

Published:2006-01 Issue:1 Volume:51 Page:71-77
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Uramoto Hidetaka,Sugio Kenji,Oyama Tsunehiro,Ono Kenji,Sugaya Masakazu,Yoshimatsu Takashi,Hanagiri Takeshi,Morita Masaru,Yasumoto Kosei

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Cancer burden in the year. The global picture;Parkin;Eur J Cancer,2001

2. Genetic testing for chemotherapy in non-small cell lung cancer;Rosell;Lung Cancer,2003

3. ErbB-targeted therapeutic approaches in human cancer;Arteaga;Exp Cell Res,2003

4. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839: Iressa): tablets;Cohen;Clin Cancer Res,2004

5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of long non-coding RNA in drug resistance in non-small cell lung cancer;Thoracic Cancer;2018-05-03

2. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors;Journal of Thoracic Oncology;2018-03

3. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors;The Journal of Molecular Diagnostics;2018-03

4. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology;Archives of Pathology & Laboratory Medicine;2018-01-22

5. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?;Lung Cancer;2015-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3